Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RQ-00317076
- Development stage
- Unknown
- Lead developer
- RaQualia Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RQ-00317076 (also known as AAT-076) is a selective cyclooxygenase-2 (COX-2) inhibitor small molecule developed by RaQualia Pharma for the treatment of pain in both human and veterinary medicine. As a selective COX-2 inhibitor, it aims to reduce the production of pro-inflammatory prostaglandins while sparing the COX-1 enzyme, which is responsible for maintaining gastrointestinal mucosal integrity. This selectivity is intended to provide potent analgesic and anti-inflammatory effects with a lower risk of gastrointestinal side effects compared to non-selective NSAIDs. The drug has completed Phase 2a clinical trials in the United States for post-operative pain in humans and is being explored for various veterinary applications, including the management of pain and inflammation in companion animals.
02
Targets
Beyond the preview
Go deeper on RQ-00317076.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RQ-00317076.